TG Therapeutics | TGTX - Interest Expense On Debt


TG Therapeutics reported $6.53M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 653M 32M Dec/2025
Ardelyx USD 5.76M 37K Dec/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Curis USD 178K 441K Dec/2023
Gilead Sciences USD 255M 1000K Dec/2025
Infinity Pharmaceuticals USD 45K 0 Jun/2023
J&J USD 18M 290M Sep/2025
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Novartis USD 304M 23M Dec/2025
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 6.53M 187K Dec/2025
Verastem USD 415K 733K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025